Recent developments coming out of Abbott Laboratories could rock the foundation of the transcatheter aortic valve replacement market.

Cordis is recalling thousands of angiographic catheters due to a problem with marker bands.

The Irvine, CA-based company has raised $4 million in a series A and won a $1.5 million NIH grant to take its wearable through clinical trials.

Quentin Blackford, currently Dexcom's COO, will become iRhythm Technologies' president and CEO beginning in early October.

The Chelmsford, MA-based company is acquiring Itamar Medical for about $538 million.

Junkosha shared its new solutions for increasing signal capacity in electrophysiology catheters during MD&M West 2021.

The Irvine, CA-based company would help boost Abbott’s vascular offerings.

The latest generation of Medtronic's self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX, is designed to enhance ease-of-use and predictable valve deployment.

The EMPOWER trial will evaluate Cardiac Dimensions’ Carillon Mitral Contour System and look at about 300 patients at 75 sites.

A total of 10 patients will be enrolled into the feasibility study, which, if successful, will lead to a larger erectile dysfunction study involving around 50 patients.